다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

홈
인베스팅
주식
미국
NASDAQ
Inhibikase Therapeutics Inc (IKT)
Inhibikase Therapeutics Inc (IKT) 뉴스

IKT

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:IKT

1 2 3 4 5 6 7 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/22	21:55	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/20	21:55	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/20	21:01	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/20	20:09	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/16	09:00	GlobeNewswire Inc.	Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/16	06:04	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/15	21:45	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/15	20:56	Edgar (US Regulatory)	Form RW - Registration Withdrawal Request	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/10	03:41	Edgar (US Regulatory)	Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/05/09	21:00	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/04/19	05:30	GlobeNewswire Inc.	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/04/03	21:05	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/03/28	05:15	GlobeNewswire Inc.	Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/03/07	22:30	GlobeNewswire Inc.	Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/02/29	06:05	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/02/07	21:59	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/02/07	21:55	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/02/02	06:49	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/02/02	06:09	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/01/29	23:05	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/01/17	06:31	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IKT	Inhibikase Therapeutics Inc
2024/01/17	06:05	GlobeNewswire Inc.	Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/12/19	22:30	GlobeNewswire Inc.	Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/12/04	22:35	GlobeNewswire Inc.	Inhibikase Therapeutics Granted Pre-NDA Meeting with the FDA for IkT-001Pro	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/11/15	06:30	GlobeNewswire Inc.	Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Period Activity	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/11/07	23:28	GlobeNewswire Inc.	Correcting & Replacing -- Inhibikase Therapeutics to Report Third Quarter Financial Results on November 14, 2023	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/11/07	22:00	GlobeNewswire Inc.	Inhibikase Therapeutics to Report Second Quarter Financial Results on November 14, 2023	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/10/17	06:24	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/10/16	20:00	GlobeNewswire Inc.	Inhibikase Therapeutics Highlights Unblinded Functional Analysis from the 201 Trial of Risvodetinib in Untreated Parkinson’s Disease and Provides Update on Ongoing Enrollment	NASDAQ:IKT	Inhibikase Therapeutics Inc
2023/10/04	21:30	GlobeNewswire Inc.	Inhibikase Therapeutics Receives FDA Orphan Drug Designation for Risvodetinib for the Treatment of Multiple System Atrophy	NASDAQ:IKT	Inhibikase Therapeutics Inc

검색 관련기사 보기:NASDAQ:IKT

1 2 3 4 5 6 7 다음 >>

BlackRock Japan

BNP PARIBAS ISSUANCE

Jpmorgan Chase Financial...

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관